Joint Task Force Report on Omalizumab-associated Anaphylaxis

The Joint Task Force concluded that 39,510 patients received Xolair (omalizumab) between 2003 and 2005. From this group, 35 patients had 41 episodes of anaphylaxis related to Xolair. Calculated anaphylaxis-reporting rate was 0.09% of patients, 61% of reactions occurred in the first 2 hours after one of the first 3 doses. Omalizumab binds to Cε3 region of IgE.

An observation period of 2 hours for the first 3 injections and 30 minutes for subsequent injections would have captured 75% of the anaphylactic reactions.

Click here for a case report of a delayed allergic reactions to omalizumab.

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. J Allergy Clin Immunol. 2007 Dec;120(6):1373-7. Epub 2007 Nov 9.
Delayed allergic reactions to omalizumab: Are patients reporting all cases? JACI, 03/2008.
Image source: Wikipedia, public domain.
Images: Mechanisms of action of omalizumab. JACI, 02/2008.

Updated: 03/08/2008

No comments:

Post a Comment